此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

对2岁及2岁以上的儿童患有中度至重度湿疹的儿童的长期研究称为Abrocitinib

2026年11月3日 更新者:Pfizer

第3阶段,多中心,长期开放标签研究,评估了艾布罗替尼的安全性和有效性,有或没有局部药物为2岁及2岁以上的儿科参与者接受中等性皮肤炎的儿科参与者

This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.

研究概览

地位

招聘中

详细说明

Phase 3, open-label study to assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children ≥2 years of age with moderate-to-severe atopic dermatitis (AD). This study will enroll participants in two cohorts: an extension cohort of participants who previously completed prior abrocitinib studies, and a de novo cohort of participants (6 to <12 years of age) who have not participated in previous abrocitinib studies. Study duration will be up to 2 years (or commercial availability, whichever occurs earlier). The study will enroll a maximum of approximately 500 participants with moderate-to-severe Atopic Dermatitis from study sites globally (extension cohort will enroll up to 320 participants; de novo cohort will enroll approximately 180 participants). All participants will receive the study intervention abrocitinib oral suspension.

研究类型

介入性

注册 (估计的)

450

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Shanghai、中国、200062
        • 招聘中
        • Shanghai Children's Hospital
      • Shanghai、中国、200092
        • 招聘中
        • Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100045
        • 招聘中
        • Beijing Children's hospital, Capital Medical University
    • Guangdong
      • Shenzhen、Guangdong、中国、518026
        • 招聘中
        • Shenzhen Children's Hospital
    • Hunan
      • Changsha、Hunan、中国、410007
        • 招聘中
        • Hunan Children's Hospital
    • Jiangxi
      • Nanchang、Jiangxi、中国、330000
        • 尚未招聘
        • Dermatology Hospital of Jiangxi Province
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310009
        • 招聘中
        • Hangzhou Third People's Hospital
    • Baranya
      • Pécs、Baranya、匈牙利、7632
        • 招聘中
        • Pécsi Tudományegyetem Klinikai Központ
    • Bekes County
      • Békéscsaba、Bekes County、匈牙利、5600
        • 招聘中
        • Trial Pharma Kft.
    • Csongrád-csanád
      • Szeged、Csongrád-csanád、匈牙利、6720
        • 尚未招聘
        • University of Szeged
    • Pest County
      • Budapest、Pest County、匈牙利、1033
        • 招聘中
        • Clinexpert Kft.
      • Chihuahua City、墨西哥、31238
        • 尚未招聘
        • Servicios Hospitalarios de Mexico S.A. DE C.V.
    • Mexico City
      • Mexico City、Mexico City、墨西哥、06720
        • 尚未招聘
        • Hospital Infantil de Mexico Federico Gomez
    • Nuevo León
      • Monterrey、Nuevo León、墨西哥、64718
        • 尚未招聘
        • Eukarya Pharmasite S.C.
    • Veracruz Ignacio de LA Llave
      • Veracruz、Veracruz Ignacio de LA Llave、墨西哥、91900
        • 尚未招聘
        • Arké SMO S.A de C.V
      • Fukuoka、日本、811-1394
        • 招聘中
        • Fukuoka National Hospital
      • Fukuoka、日本、819-0042
        • 招聘中
        • Saruta Dermatology Clinic
    • Kanagawa
      • Yokohama、Kanagawa、日本、220-6208
        • 招聘中
        • Queen's square Medical Facilities Queen's square Dermatology and Allergology
    • Osaka
      • Sakai、Osaka、日本、593-8324
        • 招聘中
        • Dermatology and Ophthalmology Kume Clinic
    • Tokyo
      • Setagaya-ku、Tokyo、日本、157-0066
        • 招聘中
        • Sasamoto Children's Clinic
    • Lesser Poland Voivodeship
      • Krakow、Lesser Poland Voivodeship、波兰、30-002
        • 招聘中
        • Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka cywilna
    • Lublin Voivodeship
      • Lublin、Lublin Voivodeship、波兰、20-573
        • 招聘中
        • LUXDERM Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska
    • Masovian Voivodeship
      • Warsaw、Masovian Voivodeship、波兰、02-625
        • 招聘中
        • Centrum Medyczne Evimed
    • Silesian Voivodeship
      • Chorzów、Silesian Voivodeship、波兰、41-500
        • 招聘中
        • DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gebska
    • Łódź Voivodeship
      • Lodz、Łódź Voivodeship、波兰、90-436
        • 招聘中
        • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
    • Świętokrzyskie Voivodeship
      • Ostrowiec Świętokrzyski、Świętokrzyskie Voivodeship、波兰、27-400
        • 招聘中
        • Dermedic Jacek Zdybski
    • Alabama
      • Birmingham、Alabama、美国、35244
        • 招聘中
        • Cahaba Dermatology & Skin Health Center
    • Arkansas
      • North Little Rock、Arkansas、美国、72117
        • 招聘中
        • Arkansas Research Trials
    • California
      • San Diego、California、美国、92123
        • 招聘中
        • Investigational Drug Service - Rady Childrens Hospital-San Diego
      • San Diego、California、美国、92123
        • 招聘中
        • University of California, San Diego/ Rady Children's Hospital - San Diego
    • Florida
      • Jacksonville、Florida、美国、32256
        • 招聘中
        • Solutions Through Advanced Research
    • Idaho
      • Meridian、Idaho、美国、83646
        • 招聘中
        • Ada West Research - Meridian
    • Indiana
      • Indianapolis、Indiana、美国、46250
        • 招聘中
        • Dawes Fretzin Clinical Research Group, LLC
    • Missouri
      • St Louis、Missouri、美国、63104
        • 招聘中
        • Saint Louis University
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • 招聘中
        • Medical University of South Carolina - South Carolina Translational Research Nexus Clinic
      • Greenville、South Carolina、美国、29607
        • 招聘中
        • Tribe Clinical Research, LLC
    • Texas
      • San Antonio、Texas、美国、78235
        • 招聘中
        • Texas Dermatology and Laser Specialists
      • Zaragoza、西班牙、50009
        • 招聘中
        • Hospital Universitario Miguel Servet
    • A Coruña [LA Coruña]
      • Santiago de Compostela、A Coruña [LA Coruña]、西班牙、15706
        • 招聘中
        • CHUS - Hospital Clinico Universitario
    • Barcelona
      • Granollers、Barcelona、西班牙、08402
        • 招聘中
        • Hospital General de Granollers

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

2年 至 11年 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria for the Extension Cohort:

1. Participants who have completed the treatment phase of the qualifying parent study (age 2 to <12 years old).

• No contraception methods are required for male participants. Female participants must not be pregnant or breastfeeding and, if the participant is of child-bearing potential, must use a highly effective form of contraception (i.e., abstinence) during the study intervention period and for at least 28 days after the last dose of study intervention.

Inclusion Criteria for the De Novo Cohort:

Age

  1. Children aged 6 to <12 years at the time of informed consent/assent.

    • No contraception methods are required for male participants.

    Disease Characteristics:

  2. Participants who meet all of the following AD criteria:

    • A documented diagnosis of chronic AD for at least 6 months prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria; and
    • A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and
    • Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy.

    Other Inclusion Criteria:

  3. Body weight ≥15 kg

Exclusion Criteria for the Extension Cohort:

Medical Conditions:

  1. Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

    If the participant has SDQ total score ≥17, the investigator should exclude the child or refer them to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.

    Prior/Concomitant Therapy:

  2. Required use of any prohibited concomitant treatments outlined in Section 6.9.3 and Appendix 9 of study protocol.

  3. Required vaccination with live attenuated vaccines during study treatment and for 6 weeks after discontinuing study treatment.

    Diagnostic Assessments:

  4. Ongoing adverse event in the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern OR the participant is currently triggering safety monitoring criteria.

  5. Discontinued from treatment early in the parent studies OR triggered a discontinuation criterion at any point during the parent studies OR meets exclusion criteria from the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern.

Exclusion Criteria for the De Novo Cohort

Medical Conditions:

  1. Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

    If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.

  2. Have any of the following medical conditions:

    • Infections:

      • Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (baseline) or have superficial skin infections within 1 week of Day 1.
      • History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.
      • Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
      • Infection with HIV, hepatitis B, and/or hepatitis C
      • Evidence of active TB or inadequately treated latent TB.
    • Skin Conditions:

      - Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.

    • Other Conditions:

      • Documented history of skeletal dysplasia.
      • Documented history of retinal detachment.
      • History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
      • Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
      • Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
      • Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.

    Prior/Concomitant Therapy:

  3. Prior treatment with a systemic JAK inhibitor for AD.

  4. Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.

  5. Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes and strong inducers of CYP2C9 enzymes is not allowed in the study.

    Prior/Concurrent Clinical Study Experience:

  6. Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.

    Diagnostic Assessments:

  7. Hepatic and/or renal and/or hematological abnormalities defined as:

    • AST >2 x ULN
    • Hemoglobin <10 g/dL
    • ALT >2 x ULN
    • ANC <1000/mm3
    • Total bilirubin ≥1.5 x ULN
    • ALC <500/mm3
    • eGFR <60 mL/min/1.73 m2
    • Platelets <150,000 /mm3

    Other Exclusion Criteria:

  8. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Extension

Patients who have completed other abrocitinib studies

Abrocitinib administered as liquid oral suspension.

其他名称:
  • PF-04965842
实验性的:De novo

Patients who have not participated other abrocitinib studies

Abrocitinib administered as liquid oral suspension.

其他名称:
  • PF-04965842

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and adverse events (AEs) that lead to study discontinuation
大体时间:0-24 months

The number of the treatment emergent adverse events, serious adverse events and adverse events leading to discontinuation among patients with moderate-to-severe disease treated with abrocitinib regardless of discontinuation from study treatment.

0-24 months

次要结果测量

结果测量
措施说明
大体时间
Number of Participants With Clinically Significant Laboratory Abnormalities
大体时间:0-24 months

The number of clinically significant laboratory abnormalities among participants with moderate-to-severe disease treated with abrocitinib.

0-24 months
Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a 2 -point reduction from baseline at all scheduled time points
大体时间:Baseline, 24 months

Proportion of responders based on vIGA at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib

Baseline, 24 months
Percentage of Response based on achieving a ≥4 point improvement from baseline in the Worst Itch Numerical Rating Scale (WI-NRS) at all scheduled time points in participants aged ≥2 to <6 years
大体时间:0-24 months

Percentage of responders based on achieving an improvement ≥4 points from baseline at all scheduled time points in the WI-NRS (in patients aged ≥2 to <6 years) with moderate-to-severe disease treated with abrocitinib.

0-24 months
Percentage of Response based on achieving a ≥4-point improvement from baseline in the WSI-NRS at all scheduled time points in participants aged ≥6 to 12 years
大体时间:0-24 months

Percentage of responders based on achieving an improvement ≥4 points from baseline at all scheduled time points in the WSI-NRS (in patients aged ≥6 to 12 years) with moderate-to-severe disease treated with abrocitinib.

0-24 months
Percentage of Responders based on achieving Eczema Area and Severity Index (EASI)-50, EASI-90 and EASI-100 at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib
大体时间:0-24 months

Percentage of response based on achieving ≥50%, ≥90%, 100% improvement from parent study baseline in the EASI total score (EASI-50, EASI-90, EASI-100) at all scheduled time points.

0-24 months
Percent Change from Baseline (CFB) in EASI total score at all scheduled time points.
大体时间:0-24 months

Mean percent CFB in EASI total score at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib

0-24 months
Percentage of Participants with Flares
大体时间:0-24 months

Percentage of participants reporting flares in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in the percentage Body Surface Area (BSA) affected at all scheduled time points
大体时间:0-24 months

Mean CFB in BSA affected at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Children's Dermatology Life Quality Index (CDLQI) at all scheduled time points.
大体时间:0-24 months

Mean CFB in CDLQI at all scheduled time points in participants aged ≥4 to <16 years with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in in Infants' Dermatitis Quality of Life (IDQOL) Index at all scheduled time points
大体时间:0-24 months

Mean CFB in IDQOL Index or CDQLI depending on age at all scheduled time points in participants aged <4 years with moderate-to-severe disease treated with abrocitinib

0-24 months
CFB in Patient-Oriented Eczema Measure (POEM) at all scheduled time points
大体时间:0-24 months

Mean CFB in POEM at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Dermatitis Family Impact (DFI) at all scheduled time points
大体时间:0-24 months

Mean CFB in DFI at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Patient Global Impression of Severity (PGIS) at all scheduled time points
大体时间:0-24 months

Mean CFB in PGIS (in patients aged 6 to <12 years) at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Observer Reported Global Impression of Severity (OGIS) at all scheduled time points
大体时间:0-24 months

Mean CFB in OGIS (in patients aged 2 to <6 years) at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib

0-24 months
CFB in the the EuroQol- 5 Dimension Youth (EQ-5D-Y)
大体时间:0-24 months

Mean CFB in EQ-5D-Y at all scheduled time points in patients with moderate-tosevere AD treated with abrocitinib versus placebo.

0-24 months
Number of topical corticosteroid and /or topical calcineurin inhibitor free days
大体时间:0-24 months

Mean number of days free from topical corticosteroids and /or topical calcineurin inhibitor use in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
Percentage of Participants Achieving satisfactory response in Tdap/DTaP and/or pneumococcal antibody titers as appropriate in participants who receive Tdap/DTaP and/or pneumococcal vaccinations
大体时间:0-24 months

For patients that receive Tdap/ DTap and/or pneumococcal vaccinations during the study, the proportion of patients treated with abrocitinib who achieve satisfactory immunogenicity at 4 weeks after receiving the vaccinations.

0-24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Pfizer CT.gov Call Center、Pfizer

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月2日

初级完成 (估计的)

2032年2月22日

研究完成 (估计的)

2032年2月22日

研究注册日期

首次提交

2025年1月29日

首先提交符合 QC 标准的

2025年1月29日

首次发布 (实际的)

2025年2月4日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅